Healthpeak Properties (DOC) Panoramica del titolo
Healthpeak Properties, Inc. è un fondo di investimento immobiliare (REIT) completamente integrato e una società S&P 500. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
DOC Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Healthpeak Properties, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$20.66 |
| Massimo di 52 settimane | US$22.95 |
| Minimo di 52 settimane | US$15.70 |
| Beta | 1.0 |
| Variazione di 1 mese | -4.92% |
| Variazione a 3 mesi | 5.62% |
| Variazione di 1 anno | 20.54% |
| Variazione a 3 anni | 2.08% |
| Variazione a 5 anni | -41.49% |
| Variazione dall'IPO | 288.89% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 07
DOC: Higher 2026 Outlook And JV Will Mask Deepening Margin Pressure
Analysts have raised their price target for Healthpeak Properties from $17.00 to about $17.71. The updated target reflects revised assumptions that incorporate a slightly higher discount rate, more conservative expectations for revenue and profit margins, and a significantly higher projected future P/E multiple.Seeking Alpha • Aug 05
Healthpeak Properties: A Well-Covered 5.6% Yield, But Life Science Recovery Remains Key
Summary Healthpeak Properties remains in growth mode, supported by a well-covered 5.6% dividend yield and low leverage at 4.7x net debt/EBITDAre. Janus Living, DOC’s senior housing spin-off, is delivering strong results and materially contributes to DOC’s market cap and growth outlook. Lab segment occupancy is improving, signaling a potential inflection in the life science sector, though this comes with elevated capital expenditures. Dividend coverage remains robust, with a payout ratio of 70–80%, and management has authorized a $500 million share repurchase program. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.Recent updates
Aggiornamento narrativa • Aug 07
DOC: Higher 2026 Outlook And JV Will Mask Deepening Margin Pressure
Analysts have raised their price target for Healthpeak Properties from $17.00 to about $17.71. The updated target reflects revised assumptions that incorporate a slightly higher discount rate, more conservative expectations for revenue and profit margins, and a significantly higher projected future P/E multiple.Seeking Alpha • Aug 05
Healthpeak Properties: A Well-Covered 5.6% Yield, But Life Science Recovery Remains Key
Summary Healthpeak Properties remains in growth mode, supported by a well-covered 5.6% dividend yield and low leverage at 4.7x net debt/EBITDAre. Janus Living, DOC’s senior housing spin-off, is delivering strong results and materially contributes to DOC’s market cap and growth outlook. Lab segment occupancy is improving, signaling a potential inflection in the life science sector, though this comes with elevated capital expenditures. Dividend coverage remains robust, with a payout ratio of 70–80%, and management has authorized a $500 million share repurchase program. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.Aggiornamento narrativa • Jul 10
DOC: Index Additions And Higher Earnings Outlook Will Support Future Upside
Analysts have raised their price target for Healthpeak Properties from $25.80 to $26.94, citing updated assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for Healthpeak Properties Healthpeak Properties, Inc.
Aggiornamento narrativa • Jun 26
DOC: Buybacks And Raised Earnings Guidance Will Support Measured Future Upside Potential
Analysts have slightly increased their price target on Healthpeak Properties to $21.44 from $20.83, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News for Healthpeak Properties Healthpeak Properties reported a share repurchase activity from January 1, 2026 to May 5, 2026, buying back 5,950,000 shares for US$100 million, representing 0.86% of its shares, according to a buyback tranche update.Aggiornamento narrativa • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.Aggiornamento narrativa • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).Aggiornamento narrativa • May 13
DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook
Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).Aggiornamento narrativa • Apr 28
DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).Aggiornamento narrativa • Apr 14
DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential
Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.Aggiornamento narrativa • Mar 31
DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential
Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.Aggiornamento narrativa • Mar 16
DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential
Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.Aggiornamento narrativa • Mar 02
DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside
Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.Aggiornamento narrativa • Feb 16
DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects
Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.Aggiornamento narrativa • Feb 02
DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential
Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.Aggiornamento narrativa • Jan 19
DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential
Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.Aggiornamento narrativa • Jan 05
DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).Aggiornamento narrativa • Dec 14
DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.Aggiornamento narrativa • Nov 30
DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward
Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.Aggiornamento narrativa • Nov 16
DOC: Discount Rate Improvements Will Drive Margin Gains Ahead
Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.Aggiornamento narrativa • Nov 01
DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential
Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).Aggiornamento narrativa • Oct 17
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.Aggiornamento narrativa • Oct 03
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.Aggiornamento narrativa • Sep 17
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.Aggiornamento narrativa • Sep 02
Outpatient And Life Science Trends Will Create Future Opportunities
The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.Aggiornamento narrativa • Aug 19
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.Seeking Alpha • Apr 10
Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside
Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Why Healthpeak Is A Smart Buy For Income Investors
Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
A REIT Geek Who Likes Healthpeak
Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Healthpeak Properties: I'm Buying The 6% Dividend Yield
Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Healthpeak: Potential Upside Still Exists, But Don't Expect Much
Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
Nuova narrativa • Aug 21
Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth
Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.Seeking Alpha • Jul 18
Healthpeak: Missing The Boat Above $20/Share
Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking AlphaRendimenti per gli azionisti
| DOC | US Health Care REITs | US Mercato | |
|---|---|---|---|
| 7D | -5.2% | -3.4% | 0.09% |
| 1Y | 20.5% | 26.1% | 19.0% |
Ritorno vs Industria: DOC ha avuto una performance inferiore rispetto al US Health Care REITs che ha registrato un rendimento 26.1 % nell'ultimo anno.
Rendimento vs Mercato: DOC ha superato il mercato US che ha restituito 19 % nell'ultimo anno.
Volatilità dei prezzi
| DOC volatility | |
|---|---|
| DOC Average Weekly Movement | 3.5% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: DOC non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di DOC è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1985 | 411 | Scott Brinker | www.healthpeak.com |
Healthpeak Properties, Inc. è un fondo di investimento immobiliare (REIT) completamente integrato e una società quotata nell’indice S&P 500. Healthpeak possiede, gestisce e sviluppa immobili di alta qualità destinati alla ricerca e all’erogazione di servizi sanitari. Healthpeak Properties, Inc. ha sede a Denver, in Colorado.
Healthpeak Properties, Inc. Riepilogo dei fondamenti
| DOC statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$14.41b |
| Utili (TTM) | US$242.74m |
| Ricavi(TTM) | US$2.95b |
58.7x
Rapporto P/E4.8x
Rapporto P/SDOC è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DOC Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.95b |
| Costo del fatturato | US$1.25b |
| Profitto lordo | US$1.70b |
| Altre spese | US$1.46b |
| Utili | US$242.74m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.35 |
| Margine lordo | 57.65% |
| Margine di profitto netto | 8.23% |
| Rapporto debito/patrimonio netto | 105.6% |
Come si è comportato DOC nel lungo periodo?
Vedi performance storica e confrontoDividendi
5.9%
Rendimento attuale del dividendo67%
Rapporto di remunerazioneDOC paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di DOC| Healthpeak Properties date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Aug 17 2026 |
| Data di pagamento dei dividendi | Aug 28 2026 |
| Giorni fino al dividendo Ex | 4 days |
| Giorni prima della data di pagamento dei dividendi | 15 days |
DOC paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di DOCAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/12 00:46 |
| Prezzo dell'azione a fine giornata | 2026/08/12 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Healthpeak Properties, Inc. è coperta da 38 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Adam Feinstein | Barclays |